LA JOLLA, Calif.
, Feb. 5, 2014
Auspex Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a public offering price of $12.00
per share. Auspex has granted the underwriters a 30-day option to purchase up to an aggregate of 1,050,000 additional shares of common stock at the initial public offering price to cover any over-allotments. The shares are expected to begin trading on the NASDAQ Global Market, beginning on February 5, 2014
, under the symbol "ASPX." The offering is expected to close on February 10, 2014
, subject to customary closing conditions.
The joint book-running managers for the offering are Stifel and BMO Capital Markets. In addition, Robert W. Baird & Co. Incorporated, William Blair and Company, L.L.C. and Ladenburg Thalmann & Co. Inc. are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 4, 2014. The offering is being made by means of a prospectus, copies of which may be obtained from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attention: Syndicate, by telephone at (415) 364-2720 or by email to SyndicateOps@stifel.com, or from BMO Capital Markets Corp., 3 Times Square, 27th Floor, New York, NY 10036, Attention: Equity Syndicate Department, by telephone at (800) 414-3627 or by email to firstname.lastname@example.org.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Auspex Pharmaceuticals
Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. Auspex's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington's disease, tardive dyskinesia and Tourette syndrome, as well as other orphan indications. Auspex's lead product candidate, SD-809, is in a Phase 3 registration clinical trial for the treatment of chorea (abnormal involuntary movements) associated with Huntington's disease. Auspex has employed its deuterium chemistry approach to optimize other deuterium-containing compounds in its portfolio that are at various stages of development. For further information, please visit the company's website, www.auspexpharma.com.
SOURCE Auspex Pharmaceuticals